Thus, future therapeutic approaches that can promote increased expression/activation of PKR and phosphorylation of eIF2α may be an effective modality of treatment for breast cancer patients whose breast tumors do not demonstrate elevated PKR. This evidence concerns the gene EIF2A and breast carcinoma.